[go: up one dir, main page]

CO2019009080A2 - Péptidos y métodos para el tratamiento de diabetes - Google Patents

Péptidos y métodos para el tratamiento de diabetes

Info

Publication number
CO2019009080A2
CO2019009080A2 CONC2019/0009080A CO2019009080A CO2019009080A2 CO 2019009080 A2 CO2019009080 A2 CO 2019009080A2 CO 2019009080 A CO2019009080 A CO 2019009080A CO 2019009080 A2 CO2019009080 A2 CO 2019009080A2
Authority
CO
Colombia
Prior art keywords
diabetes
peptides
treatment
methods
hcpycslqplalegslqkrg
Prior art date
Application number
CONC2019/0009080A
Other languages
English (en)
Inventor
Elst Luc Vander
Vincent Carlier
Jean-Marie Saint-Remy
Original Assignee
Imcyse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imcyse Sa filed Critical Imcyse Sa
Publication of CO2019009080A2 publication Critical patent/CO2019009080A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)

Abstract

La invención se refiere a péptidos tales como HCPYCSLQPLALEGSLQKRG y a su uso en el tratamiento de diabetes tipo 1 y a la generación de célula T CD4+ citolítica.
CONC2019/0009080A 2017-03-09 2019-08-22 Péptidos y métodos para el tratamiento de diabetes CO2019009080A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17160085 2017-03-09
PCT/EP2018/055501 WO2018162498A1 (en) 2017-03-09 2018-03-06 Peptides and methods for the treatment of diabetes

Publications (1)

Publication Number Publication Date
CO2019009080A2 true CO2019009080A2 (es) 2019-08-30

Family

ID=58266442

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0009080A CO2019009080A2 (es) 2017-03-09 2019-08-22 Péptidos y métodos para el tratamiento de diabetes

Country Status (21)

Country Link
US (4) US10808016B2 (es)
EP (1) EP3592765A1 (es)
JP (2) JP7102430B2 (es)
KR (1) KR20190126798A (es)
CN (1) CN110536898B (es)
AU (2) AU2018229741B2 (es)
BR (1) BR112019018616A2 (es)
CA (1) CA3051518A1 (es)
CO (1) CO2019009080A2 (es)
CU (1) CU24596B1 (es)
IL (1) IL268874B2 (es)
MX (1) MX2019010558A (es)
MY (1) MY192295A (es)
NZ (1) NZ755744A (es)
PE (1) PE20191529A1 (es)
PH (1) PH12019502036A1 (es)
RU (1) RU2761653C2 (es)
SA (1) SA519410007B1 (es)
SG (1) SG11201908275XA (es)
WO (1) WO2018162498A1 (es)
ZA (1) ZA201905851B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
WO2009101206A2 (en) * 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7102430B2 (ja) 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20230136112A1 (en) * 2019-11-27 2023-05-04 Imcyse Sa Methods for stratifying diabetes patients
WO2021224403A1 (en) * 2020-05-06 2021-11-11 Imcyse Sa Immunogenic peptides with new oxidoreductase motifs
JP2023525276A (ja) 2020-05-06 2023-06-15 アンシス・エスア 延長された酸化還元酵素モチーフを有する免疫原性ペプチド
CA3182369A1 (en) * 2020-05-06 2021-07-22 Imcyse Sa Combination treatment for fumarate-related diseases
BR112023024546A2 (pt) 2021-06-01 2024-02-15 Imcyse Sa Métodos de tratamento usando peptídeos imunogênicos

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9078843B2 (en) * 2005-09-22 2015-07-14 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom
PT2476435T (pt) 2006-08-11 2018-03-05 Life Sciences Res Partners Vzw Péptidos imunogénicos e a sua utilização em distúrbios imunitários
AU2009214041A1 (en) * 2008-02-14 2009-08-20 Katholieke Universiteit Leuven CD4+ T-cells with cytolytic properties
CA2715611C (en) 2008-02-14 2018-03-13 Life Sciences Research Partners Vzw Immunotherapy targeting intracellular pathogens
WO2009101204A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Elimination of immune responses to viral vectors
US9248171B2 (en) 2008-02-14 2016-02-02 Imcyse Sa Immunogenic peptides and their use in transplantation
US8999346B2 (en) 2008-02-14 2015-04-07 Life Sciences Research Partners Vzw Immunogenic control of tumours and tumour cells
WO2009101206A2 (en) 2008-02-14 2009-08-20 Life Sciences Research Partners Vzw Strategies to prevent and/or treat immune responses to soluble allofactors
CN103002909B (zh) 2010-03-29 2016-06-29 国家科学研究中心 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
GB201201511D0 (en) * 2012-01-30 2012-03-14 Univ Leuven Kath Modified epitopes for boosting CD4+ T-cell responses
GB201309469D0 (en) * 2013-05-28 2013-07-10 Imcyse Sa Detection of CD4+ T lymphocytes
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
GB201418433D0 (en) 2014-10-17 2014-12-03 Imcyse Sa Novel immunogenic peptides
JP7102430B2 (ja) * 2017-03-09 2022-07-19 アンシス・エスア 糖尿病の治療のためのペプチド及び方法
US20210401976A1 (en) * 2018-11-12 2021-12-30 Imcyse Sa Immunogenic peptides with improved oxidoreductase motifs
TWM593454U (zh) 2019-11-11 2020-04-11 競泰股份有限公司 多鑰匙鎖心

Also Published As

Publication number Publication date
CA3051518A1 (en) 2018-09-13
BR112019018616A2 (pt) 2020-04-28
JP2020509067A (ja) 2020-03-26
CN110536898B (zh) 2023-09-08
CN110536898A (zh) 2019-12-03
AU2018229741B2 (en) 2021-09-02
JP7102430B2 (ja) 2022-07-19
IL268874B2 (en) 2023-09-01
MY192295A (en) 2022-08-17
IL268874B1 (en) 2023-05-01
US10808016B2 (en) 2020-10-20
RU2761653C2 (ru) 2021-12-13
US20190352348A1 (en) 2019-11-21
RU2019126232A3 (es) 2021-06-01
US11407795B2 (en) 2022-08-09
MX2019010558A (es) 2019-10-21
EP3592765A1 (en) 2020-01-15
PH12019502036A1 (en) 2020-06-15
AU2021277735A1 (en) 2021-12-23
IL268874A (en) 2019-10-31
US20240092843A1 (en) 2024-03-21
RU2019126232A (ru) 2021-04-10
PE20191529A1 (es) 2019-10-23
US20200407406A1 (en) 2020-12-31
US20220411476A1 (en) 2022-12-29
US11760782B2 (en) 2023-09-19
SA519410007B1 (ar) 2023-02-16
SG11201908275XA (en) 2019-10-30
KR20190126798A (ko) 2019-11-12
AU2018229741A1 (en) 2019-08-15
WO2018162498A1 (en) 2018-09-13
NZ755744A (en) 2023-07-28
ZA201905851B (en) 2021-04-28
JP2022125216A (ja) 2022-08-26
CU20190078A7 (es) 2020-04-02
CU24596B1 (es) 2022-05-11

Similar Documents

Publication Publication Date Title
CO2019009080A2 (es) Péptidos y métodos para el tratamiento de diabetes
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CO2017013408A2 (es) Compuestos bicíclicos heterocíclicos como agentes antituberculares.
CO2018003477A2 (es) Anticuerpos anti-pd1 y métodos de uso
DOP2016000042A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
EA201592103A2 (ru) Способы и композиции для усиления cd4+ регуляторных t-клеток
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
MY181994A (en) Immuno-modulatory progenitor (imp) cell
MX2018001074A (es) Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.
MX2017004603A (es) Metodo para modular actividad de celulas inmunes inducidas por car.
EA201691078A1 (ru) Терапевтические пептиды
MX380176B (es) Molecula ligada a antigeno inmunoactivada.
PH12017502255A1 (en) Nrf2 regulators
CL2016002245A1 (es) Anticuerpos específicos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
PE20170088A1 (es) Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
CL2018000756A1 (es) Métodos moleculares de aseguramiento de la calidad para su uso en la secuenciación
MX2020004939A (es) Fabricacion de composiciones de celulas islote y metodos de uso de las mismas.
EA201890439A1 (ru) ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА)
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
SV2017005457A (es) Poliuretanos termoplásticos novedosos, uso de este material para la preparación de marcos en t para sistemas intrauterinos y marcos en t preparados con este material
MX365438B (es) Compuestos de tipo 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostericos positivos de receptores mglur2.